MYLK4 and optic neuritis: Thus, dual ROCK/MYLK4 inhibition may simultaneously target multiple cell types—neurons, endothelial cells, microglia/macrophages, and astrocytes—providing a comprehensive therapeutic approach in NMOSD optic neuritis [33].